Due to the impact of TP53 mutations on impairment of DNA damage response and induction of apoptosis there has been great hope that nontumor cell autonomous therapeutic strategies harnessing the immune system could be used to treat TP53-mutant leukemias. The gene discussed is TP53; the disease is leukemia.